<400> 362

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 10 15

Gly Asn Gly Ser Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 . 25 30

Ala Ala Arg Ala 35

<210> 363 .

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: TPO-MIMETIC PEPTIDES

<400> 363

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly
1 5 10 15

Gly Cys Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 20 25 30

Ala Ala Arg Ala 35

<210> 364

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP PCR PRIMER

<400> 364

aaaaaaggat cctcgagatt aagcacgagc agccagccac tgacgcagag tcggacc 57

<210> 365

<211> 39

<212>	DNA	
<213>	Artificial Sequence	
	·	
<220>		
<223>	Description of Artificial Sequence: Fc-TMP PCR	
	PRIMER	
<400>	365	
aaaggt	tggag gtggtggtat cgaaggtccg actctgcgt	39
<210>	366	
<211>	42	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: INTEGRIN	
	BINDING PEPTIDE	
<400>	366	
cagtgo	getgg etgetegtge ttaatetega ggateetttt tt	42
<210>	367	
<211>	81	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence:Fc-TMP	
<400>	367	
aaaggt	ggag gtggtggtat cgaaggtccg actctgcgtc agtggctggc tgctcgtgct	60
	cgag gatcctttt t	81
	•	
<210>	368	
<211>	52	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
	Description of Artificial Sequence:Fc-TMP	
<400>	368	
	acca ccacctccac ctttacccgg agacagggag aggctcttct gc	52
J		-

```
<210> 369
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Fc-TMP-TMP
<400> 369
aaaggtggag gtggtggtat cgaaggtccg actctgcgtc agtggctggc tgctcgtgct 60
<210> 370
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: FC PCR PRIMER
<400> 370
acctccacca ccagcacgag cagccagcca ctgacgcaga gtcggacc
                                                                  48
<210> 371
<211> 66
<212> DNA
<213> Artificial Sequence
<223> Description of Artificial Sequence:Fc-TMP-TMP
      OLIGONUCLEOTIDE
<400> 371
ggtggtggag gtggcggcgg aggtattgag ggcccaaccc ttcgccaatg gcttgcagca 60
                                                                  66
cgcgca
<210> 372
<211> 76
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Fc-TMP-TMP
      OLIGONUCLEOTIDE
```

<400> 372 aaaaaaagga tcctcgagat tatgcgcgtg ctgcaagcca ttggcgaagg gttgggccct 60 76 caatacctcc gccgcc <210> 373 <211> 126 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:Fc-TNF ALPHA PCR PRIMER <220> <221> CDS <222> (1)..(126) <400> 373 aaa ggt gga ggt ggt atc gaa ggt ccg act ctg cgt cag tgg ctg 48 Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 15 10 5 1 gct gct cgt gct ggt gga ggt ggc gga ggt att gag ggc cca •96 Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro 30 25 20 126 acc ctt cgc caa tgg ctt gca gca cgc gca Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala 40 35 <210> 374 <211> 42 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence:Fc-TNF ALPHA PCR PRIMER <400> 374 Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu 15 10 Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro 30 25 20 Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala

40

35

```
<210> 375
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Fc-MMP
      INHIBITOR
<220>
<221> CDS
<222> (4)..(732)
<400> 375
ttt ttt cat atg atc gaa ggt ccg act ctg cgt cag tgg
                                                                  39
    Phe His Met Ile Glu Gly Pro Thr Leu Arg Gln Trp
                                         10
      1
<210> 376
<211> 12
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:Fc-MMP
      INHIBITOR
<400> 376
Phe His Met Ile Glu Gly Pro Thr Leu Arg Gln Trp
                                     10
<210> 377
<211> 48.
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: MMP INHIBITOR
      FC
<220>
<221> CDS
```

<222> (4)..(753)

<400> 377 age acg age cag cea ctg acg cag agt cgg ace tte gat cat atg Thr Ser Ser Gln Pro Leu Thr Gln Ser Arg Thr Phe Asp His Met 15 10 5 <210> 378 <211> 15 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: MMP INHIBITOR FC <400> 378 · Thr Ser Ser Gln Pro Leu Thr Gln Ser Arg Thr Phe Asp His Met 10 1 5 15 <210> 379 <211> 45 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: TMP-TMP-Fc OLIGONUCLEOTIDE <400> 379 45 ctggctgctc gtgctggtgg aggcggtggg gacaaaactc acaca <210> 380 <211> 51 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: INTEGRIN BINDING PEPTIDE <400> 380 51 ctggctgctc gtgctggcgg tggtggcgga gggggtggca ttgagggccc a <210> 381 ---

<211> 54

<212> DNA

```
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: INTEGRIN
     BINDING PEPTIDE
<400> 381
aagccattgg cgaagggttg ggccctcaat gccacccct ccgccaccac cgcc
                                                                  54
<210> 382
<211> 54
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: INTEGRIN
      BINDING PEPTIDE
<400> 382
accettegee aatggettge ageaegegea gggggaggeg gtggggaeaa aact
                                                                  54
<210> 383
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: INTEGRIN
      BINDING PEPTIDE
<400> 383
                                                                 27
cccaccgcct cccctgcgc gtgctgc
<210> 384
<211> 189
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: INTEGRIN
      BINDING PEPTIDE
<220>
<221> CDS
<222> (10)..(189)
```

<400> 384

ttttttcat atg atc gaa ggt ccg act ctg cgt cag tgg ctg gct gct cgt 51

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg

1 5 10

gct ggc ggt ggc gga ggg ggt ggc att gag ggc cca acc ctt cgc 99
Ala Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg
20 25 30

caa tgg ctg gct gct cgt gct ggt gga ggc ggt ggg gac aaa act ctg 147
Gln Trp Leu Ala Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu
35 40 45

gct gct cgt ggt gga ggc ggt ggg gac aaa act cac aca

Ala Ala Arg Ala Gly Gly Gly Gly Asp Lys Thr His Thr

50

55

60

<210> 385

<211> 60

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: INTEGRIN BINDING PEPTIDE

<400> 385

Met Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly
1 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp
20 25 30

Leu Ala Arg Ala Gly Gly Gly Gly Gly Asp Lys Thr Leu Ala Ala 35 40 45

Arg Ala Gly Gly Gly Gly Asp Lys Thr His Thr
50 55 60

<210> 386

<211> 141

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: INTEGRIN

## BINDING PEPTIDE

<400> 386 ctaattccgc tctcacctac caaacaatgc ccccctgcaa aaaataaatt catataaaaa 60 acatacagat aaccatctgc ggtgataaat tatctctggc ggtgttgaca taaataccac 120 141 tggcggtgat actgagcaca t <210> 387 <211> 55 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: INTEGRIN BINDING PEPTIDE <400> 387 55 cgatttgatt ctagaaggag gaataacata tggttaacgc gttggaattc ggtac <210> 388 <211> 872 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: INTEGRIN BINDING PEPTIDE <400> 388 ttattttcgt gcggccgcac cattatcacc gccagaggta aactagtcaa cacgcacggt 60 gttagatatt tatcccttgc ggtgatagat tgagcacatc gatttgattc tagaaggagg 120 gataatatat gagcacaaaa aagaaaccat taacacaaga gcagcttgag gacgcacgtc 180 gccttaaagc aatttatgaa aaaaagaaaa atgaacttgg cttatcccag gaatctgtcg 240 cagacaagat ggggatgggg cagtcaggcg ttggtgcttt atttaatggc atcaatgcat 300 taaatgetta taaegeegea ttgettaeaa aaatteteaa agttagegtt gaagaattta 360 gcccttcaat cgccagagaa tctacgagat gtatgaagcg gttagtatgc agccgtcact 420 tagaagtgag tatgagtacc ctgttttttc tcatgttcag gcagggatgt tctcacctaa 480 gcttagaacc tttaccaaag gtgatgcgga gagatgggta agcacaacca aaaaagccag 540 tgattctgca ttctggcttg aggttgaagg taattccatg accgcaccaa caggctccaa 600 gccaagcttt cctgacggaa tgttaattct cgttgaccct gagcaggctg ttgagccagg 660 tgatttctgc atagccagac ttgggggtga tgagtttacc ttcaagaaac tgatcaggga 720 tagcggtcag gtgtttttac aaccactaaa cccacagtac ccaatgatcc catgcaatga 780 gagttgttcc gttgtgggga aagttatcgc tagtcagtgg cctgaagaga cgtttggctg 840 872 atagactagt ggatccacta gtgtttctgc cc

```
<210> 389
<211> 1197
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: INTEGRIN
      BINDING PEPTIDE
<400> 389
ggcggaaacc gacgtccatc gaatggtgca aaacctttcg cggtatggca tgatagcgcc 60
cggaagagag tcaattcagg gtggtgaatg tgaaaccagt aacgttatac gatgtcgcag 120
agtatgccgg tgtctcttat cagaccgttt cccgcgtggt gaaccaggcc agccacgttt 180
ctgcgaaaac gcgggaaaaa gtcgaagcgg cgatggcgga gctgaattac attcccaacc 240
gcgtggcaca acaactggcg ggcaaacagt cgctcctgat tggcgttgcc acctccagtc 300
tggccctgca cgcgccgtcg caaattgtcg cggcgattaa atctcgcgcc gatcaactgg 360
gtgccagcgt ggtggtgtcg atggtagaac gaagcggcgt cgaagcctgt aaagcggcgg 420
tgcacaatct tctcgcgcaa cgcgtcagtg ggctgatcat taactatccg ctggatgacc 480
aggatgccat tgctgtggaa gctgcctgca ctaatgttcc ggcgttattt cttgatgtct 540
ctgaccagac acccatcaac agtattattt tctcccatga agacggtacg cgactgggcg 600
tggagcatct ggtcgcattg ggtcaccagc aaatcgcgct gttagcgggc ccattaagtt 660
ctgtctcggc gcgtctgcgt ctggctggct ggcataaata tctcactcgc aatcaaattc 720
agccgatagc ggaacgggaa ggcgactgga gtgccatgtc cggttttcaa caaaccatgc 780
aaatgctgaa tgagggcatc gttcccactg cgatgctggt tgccaacgat cagatggcgc. 840
tgggcgcaat gcgcgccatt accgagtccg ggctgcgcgt tggtgcggat atctcggtag 900
tgggatacga cgataccgaa gacagctcat gttatatccc gccgttaacc accatcaaac 960
aggattttcg cctgctgggg caaaccagcg tggaccgctt gctgcaactc tctcagggcc 1020
cgcccaatac gcaaaccgcc tctccccgcg cgttggccga ttcattaatg cagctggcac 1140
                                                                1197
gacaggtttc ccgactggaa agcggacagt aaggtaccat aggatccagg cacagga
<210> 390
<211> 61
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Fc-EMP
     OLIGONUCLEOTIDE
<400> 390
tatgaaaggt ggaggtggtg gtggaggtac ttactcttgc cacttcggcc cgctgacttg 60
                                                                61
g
```

<210> 391 <211> 72

```
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Fc-EMP
      OLIGONUCLEOTIDE
<400> 391
cggtttgcaa acccaagtca gcgggccgaa gtggcaagag taagtacctc caccaccacc 60
                                                                  72
tccacctttc at
<210> 392
<211> 57
<212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:Fc-EMP
       OLIGONUCLEOTIDE
 <400> 392
 gtttgcaaac cgcagggtgg cggcggcggc ggcggtggta cctattcctg tcatttt
                                                                   57
 <210> 393
 <211> 60
 <212> DNA
 <213> Artificial Sequence
<220>
 <223> Description of Artificial Sequence:Fc-EMP
       OLIGONUCLEOTIDE
 <400> 393
 ccaggtcagc gggccaaaat gacaggaata ggtaccaccg ccgccgccgc cgccaccctg 60
 <210> 394
 <211> 118
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:Fc-EMP PCR
        TEMPLATE
```

161

<220>

<221> CDS <222> (2)..(118)

<400> 394

t atg aaa ggt gga ggt ggt gga ggt act tac tct tgc cac ttc ggc 49

Met Lys Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly

1 10 15

ggt acc tat tcc tgt cat ttt Gly Thr Tyr Ser Cys His Phe 35 118

<210> 395

<211> 39

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence:Fc-EMP PCR TEMPLATE

<400> 395

Met Lys Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly
1 5 10 15

Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly 30

Gly Thr Tyr Ser Cys His Phe

<210> 396

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP PCR PRIMER

<400> 396

gcagaagagc ctctccctgt ctccgggtaa aggtggaggt ggtggtggag gtacttactc 60 t

<210>	397	
<211>	40	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence:Fc-EMP PCR	
	PRIMER	
<400>	397	
ctaatt	ggat ccacgagatt aaccacctg cggtttgcaa	40
<210>	398	
<211>	22	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence:Fc PRIMER	
<400>	398	
aacata	aagta cctgtaggat cg	22
<210>	399	
<211>	61	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: Fc PRIMER	
	$\cdot$	
<400>		<i>-</i> ^
agagt	agta cctccaccac cacctccacc tttacccgga gacagggaga ggctcttctg	60
C		61
<210>	400	
<211>	61	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
·		
·	Description of Artificial Sequence: EMP-Fc	

```
<400> 400
ggcccgctga cctgggtatg taagccacaa gggggtgggg gaggcggggg gtaatctcga 60
                                                                  61
g
<210> 401
<211> 50
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-Fc
      OLIGONUCLEOTIDE
<400> 401
gatectegag attacecee geeteeceea ecceettgtg gettacatae
                                                                  50
<210> 402
<211> 118
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-Fc PCR
      TEMPLATE
<220>
<221> CDS
<222> (1)..(108)
<400> 402
gtt tgc aaa ccg cag ggt ggc ggc ggc ggc ggt ggt acc tat tcc
                                                                  48
Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser
                                                         15
                                     10
  1
tgt cat ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg
                                                                  96
Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly
                                                     30
                                 25
             20
                                                                  118
gga ggc ggg ggg taatctcgag
Gly Gly Gly Gly
         35
<210> 403
```

<211> 36

PCT/US99/25044 WO 00/24782

```
<212> PRT
```

<213> Artificial Sequence <223> Description of Artificial Sequence: EMP-Fc PCR

TEMPLATE

<400> 403

Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser 15 10 1

Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly 30 25 20

Gly Gly Gly 35

<210> 404

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EMP-Fc PCR PRIMER

<400> 404

ttatttcata tgaaaggtgg taactattcc tgtcatttt

39

<210> 405

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EMP-Fc PCR PRIMER

<400> 405

tggacatgtg tgagttttgt ccccccgcc tccccaccc cct

43

<210> 406

<211> 43 ...

<212> DNA

<213> Artificial Sequence

. WO 00/24782	PCT/US99/25044
<220> <223> Description of Artificial Sequence: Fc PRIMER	
<400> 406 aggggtggg ggagggggggggggggggggggggggggg	43
<210> 407 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: Fc PRIMER	-
<400> 407 gttattgctc agcggtggca	20
<210> 408 <211> 60 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: EMP-EMP-Fc OLIGONUCLEOTIDE	
<400> 408 tttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaa	aatatg 60
<210> 409 <211> 41 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: EMP-EMP-Fc OLIGONUCLEOTIDE	
<400> 409 taaaagttaa aactcaaatc tagaatcaaa tcgataaaaa a	41

<212> DNA

```
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-EMP-Fc
      OLIGONUCLEOTIDE
<400> 410
ggaggtactt actcttgcca cttcggcccg ctgacttggg tttgcaaacc g
                                                                  51
<210> 411
<211> 55
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-EMP-Fc
      OLIGONUCLEOTIDE
<400> 411
agtcagcggg ccgaagtggc aagagtaagt acctcccata ttttattcct ccttc
                                                                  55
<210> 412
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-EMP-Fc
      OLIGONUCLEOTIDE
<400> 412
cagggtggcg gcggcggcgg cggtggtacc tattcctgtc attttggccc gctgacctgg 60
<210> 413
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-EMP-Fc
      OLIGONUCLEOTIDE
<400> 413
aaaatgacag gaataggtac caccgccgcc gccgccgcca ccctgcggtt tgcaaaccca 60
```

PCT/US99/25044 WO 00/24782

```
<210> 414
<211> 57
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-EMP-Fc
      OLIGONUCLEOTIDE
<400> 414
gtatgtaagc cacaaggggg tgggggaggc gggggggaca aaactcacac atgtcca
                                                                  57
<210> 415
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-EMP-Fc
      OLIGONUCLEOTIDE
<400> 415
agttttgtcc ccccccctc ccccaccccc ttgtggctta catacccagg tcagcgggcc 60
<210> 416
<211> 228
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EMP-EMP-Fc PCR
      TEMPLATE
<220>
<221> CDS
<222> (58)..(228)
<400> 416
                                                                  57
ttttttatcg atttgattct agatttgagt tttaactttt agaaggagga ataaaat
atg gga ggt act tac tct tgc cac ttc ggc ccg ctg act tgg gtt tgc
                                                                  105
Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
                                                       1-5
                                     10
                  5
  1
                                                                  153
```

aaa ccg cag ggt ggc ggc ggc ggc ggt ggt acc tat tcc tgt cat

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His 20 25 30

ttt ggc ccg ctg acc tgg gta tgt aag cca caa ggg ggt ggg gga ggc 201
Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly
35 40 45

ggg ggg gac aaa act cac aca tgt cca
Gly Gly Asp Lys Thr His Thr Cys Pro
50 55

<210> 417

<211> 57

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: EMP-EMP-FC PCR TEMPLATE

<400> 417

Met Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 10 15

Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His

Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly 35

Gly Gly Asp Lys Thr His Thr Cys Pro

<210> 418

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-EMP-EMP PCR PRIMER

<400> 418

ctaattggat cctcgagatt aaccccttg tggcttacat

40

<210> 419

<211> 72

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 419

Xaa Xaa Xaa Xaa Xaa Xaa Xaa 70

<210> 420

<211> 62

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 420

Xaa Tyr Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro 1 15

Xaa Xaa Xaa Xaa Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 20 25 30

```
<210> 421
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EPO-MIMETIC
      PEPTIDE
<220>
<223> At position 2, Xaa is R, H, L or W
<220>
<223> At position 3, Xaa is M, F or I
<220>
<223> At position 6, Xaa is any of the 20 genetically
      encoded amino acid residues or a D-stereoisomer
      thereof
<220>
<223> At position 9, Xaa is D, E, I, L or V
<400> 421
Cys Xaa Xaa Gly Pro Xaa Thr Trp Xaa Cys
                                     10
  1
<210> 422
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: EPO-MIMETIC
      PEPTIDE
<400> 422
Gly Gly Thr Tyr Ser Cys His Gly Pro Leu Thr Trp Val Cys Lys Pro
                                                          15
                                      10
Gln Gly Gly
```

```
<210> 423
```

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 423

Val Gly Asn Tyr Met Ala His Met Gly Pro Ile Thr Trp Val Cys Arg
1 5 10 15

Pro Gly Gly

<210> 424

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 424

Gly Gly Pro His His Val Tyr Ala Cys Arg Met Gly Pro Leu Thr Trp

1 10 15

Ile Cys

<210> 425

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 425

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys

PCT/US99/25044

1

5

10

15

Pro Gln

<210> 426

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 426

Gly Gly Leu Tyr Ala Cys His Met Gly Pro Met Thr Trp Val Cys Gln
1 10 15

Pro Leu Arg Gly

20

<210> 427

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 427

Thr Ile Ala Gln Tyr Ile Cys Tyr Met Gly Pro Glu Thr Trp Glu Cys
1 5 10 15

Arg Pro Ser Pro Lys Ala 20

<210> 428

<211> 13

<212> PRT...

<213> Artificial Sequence

```
<220>
```

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 428

Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
1 5 10

<210> 429

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO MIMETIC PEPTIDE

<400> 429

Tyr Cys His Phe Gly Pro Leu Thr Trp Val Cys
1 5 10

<210> 430

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: UKR ANTAGONIST PEPTIDE

<400> 430

Ala Glu Pro Val Tyr Gln Tyr Glu Leu Asp Ser Tyr Leu Arg Ser Tyr 1 5 10 15

Tyr

<210> 431

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST PEPTIDE

<400> 431

Ala Glu Leu Asp Leu Ser Thr Phe Tyr Asp Ile Gln Tyr Leu Leu Arg

1 10 15

Thr

<210> 432

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST PEPTIDE

<400> 432

Ala Glu Phe Phe Lys Leu Gly Pro Asn Gly Tyr Val Tyr Leu His Ser 1 5 10 15

Ala

<210> 433

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:UKR ANTAGONIST PEPTIDE

<400> 433

Phe Lys Leu Xaa Xaa Xaa Gly Tyr Val Tyr Leu 1 5 10

<210> 434

<211> 17

```
<212> PRT
```

WO 00/24782

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: UKR ANTAGONIST PEPTIDE

<400> 434

Ala Glu Ser Thr Tyr His His Leu Ser Leu Gly Tyr Met Tyr Thr Leu

1 10 15

Asn

<210> 435

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: UKR ANTAGONIST PEPTIDE

<400> 435

Tyr His Xaa Leu Xaa Xaa Gly Tyr Met Tyr Thr
1 5 10

<210> 436

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MCA/MCP INHIBITOR

<400> 436

Arg Asn Arg Gln Lys Thr

1

5

<210> 437

<211> 4

```
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:MCA/MCP
      INHIBITOR
<400> 437
Arg Asn Arg Gln
<210> 438
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:MCA/MCP
      INHIBITOR
<400> 438
Arg Asn Arg Gln Lys
<210> 439
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:MCA/MCP
      INHIBITOR
<400> 439
Asn Arg Gln Lys Thr
  1
<210> 440
<211> 4
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence:MCA/MCP
      INHIBITOR
<400> 440
Arg Gln Lys Thr
  1
<210> 441
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial
      Sequence: INTEGRIN-BINDING PEPTIDE
<400> 441
Arg Xaa Glu Thr Xaa Trp Xaa
  1
<210> 442
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial
      Sequence: INTEGRIN-BINDING PEPTIDE
<400> 442
Arg Xaa Glu Thr Xaa Trp Xaa
<210> 443
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial
```

Sequence: INTEGRIN-BINDING PEPTIDE

```
<400> 443
Arg Gly Asp Gly Xaa
1 5
```

WO 00/24782

<220>

<210> 444
<211> 7
<212> PRT
<213> Artificial Sequence

<223> Description of Artificial Sequence: INTEGRIN-BINDING PEPTIDE

<400> 444

Cys Arg Gly Asp Gly Xaa Cys

1 5

PCT/US99/25044

WO 00/24782

1 5

<210> 447

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
 Sequence:INTEGRIN-BINDING PEPTIDE

<400> 447

Cys Pro Ser Arg Leu Asp Ser Pro Cys
1 5

<210> 448

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
Sequence:INTEGRIN-BINDING PEPTIDE

<400> 448

Xaa Xaa Xaa Arg Gly Asp Xaa Xaa Xaa 1

<210> 449

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

1

<223> Description of Artificial
 Sequence:INTEGRIN-BINDING PEPTIDE

<400> 449

Cys Xaa Cys Arg Gly Asp Cys Xaa Cys

180

PCT/US99/25044

```
<210> 450
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial
      Sequence: INTEGRIN-BINDING PEPTIDE
<400> 450
Cys Asp Cys Arg Gly Asp Cys Phe Cys
  1
<210> 451
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial
      Sequence: INTEGRIN-BINDING PEPTIDE
<400> 451
Cys Asp Cys Arg Gly Asp Cys Leu Cys
  1
<210> 452
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial
      Sequence: INTEGRIN-BINDING PEPTIDE
<400> 452
Cys Leu Cys Arg Gly Asp Cys Ile Cys
```

<210> 453 <211> 8

```
<212> PRT
```

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: INTEGRIN-BINDING PEPTIDE

<400> 453

Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa 1

<210> 454

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: INTEGRIN-BINDING PEPTIDE

<400> 454

Xaa Xaa Xaa Asp Asp Xaa Xaa Xaa Xaa Xaa 10

<210> 455

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: INTEGRIN-BINDING PEPTIDE

<400> 455

Cys Trp Asp Asp Gly Trp Leu Cys
1 5

<210> 456

<211> 9

<212> PRT ---

<213> Artificial Sequence

<220>

<223> Description of Artificial
 Sequence:INTEGRIN-BINDING PEPTIDE

<400> 456

Cys Trp Asp Asp Leu Trp Trp Leu Cys
1 5

<210> 457

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
 Sequence:INTEGRIN-BINDING PEPTIDE

<400> 457

Cys Trp Asp Asp Gly Leu Met Cys
1 5

<210> 458

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
 Sequence:INTEGRIN-BINDING PEPTIDE

<400> 458

Cys Trp Asp Asp Gly Trp Met Cys

<210> 459

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
 Sequence:INTEGRIN-BINDING PEPTIDE

<210> 460

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: INTEGRIN-BINDING PEPTIDE

<400> 460

Cys Pro Asp Asp Leu Trp Trp Leu Cys

<210> 461

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPO-MIMETIC PEPTIDE

<400> 461

Pro Xaa Xaa Xaa Xaa Xaa Xaa Thr Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa 40

<210> 462

<211> 16

<212> PRT---

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SELECTIN ANTAGONIST PEPTIDE

<400> 462

Cys Gln Asn Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Asn Glu
1 5 10 15

<210> 463

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial
 Sequence:SELECTIN-ANTAGONIST PEPTIDE

<400> 463

Ala Glu Asn Trp Ala Asp Asn Glu Pro Asn Asn Lys Arg Asn Asn Glu

1 10 15

Asp

<210> 464

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SELECTIN ANTAGONIST PEPTIDE

<400> 464

Arg Lys Asn Asn Lys Thr Trp Thr Trp Val Gly Thr Lys Lys Ala Leu

1 10 15

Thr Asn Glu

<210> 465

<211> 13

```
<212> PRT
```

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SELECTINAMINATE ANTAGONIST PEPTIDE

<400> 465

Lys Lys Ala Leu Thr Asn Glu Ala Glu Asn Trp Ala Asp 1 5 10

<210> 466

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SELECTIN ANTAGONIST PEPTIDE

<400> 466

Cys Gln Xaa Arg Tyr Thr Asp Leu Val Ala Ile Gln Asn Lys Xaa Glu
1 10 15

<210> 467

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SELECTIN ANTAGONIST PEPTIDE

<400> 467

Arg Lys Xaa Asn Xaa Xaa Trp Thr Trp Val Gly Thr Xaa Lys Xaa Leu
1 10 15

Thr Glu Glu

<210> 468

<211> 17

15

```
WO 00/24782
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SELECTIN
      ANTAGONIST PEPTIDE
<400> 468
Ala Glu Asn Trp Ala Asp Gly Glu Pro Asn Asn Lys Xaa Asn Xaa Glu
                                     10
  1
Asp
<210> 469
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SELECTIN
      ANTAGONIST PEPTIDE
```

<400> 469

Cys Xaa Xaa Xaa Tyr Thr Xaa Leu Val Ala Ile Gln Asn Lys Xaa Glu 15 10 5 1

<210> 470 <211> 19 <212> PRT <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SELECTIN ANTAGONIST PEPTIDE

<400> 470

Arg Lys Xaa Xaa Xaa Trp Xaa Trp Val Gly Thr Xaa Lys Xaa Leu 15 10 1

Thr Xaa Glu

```
<210> 471
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SELECTIN
      ANTAGONIST PEPTIDE
<400> 471
Ala Xaa Asn Trp Xaa Xaa Xaa Glu Pro Asn Asn Xaa Xaa Glu Asp
                                                         15
                                     10
  1
<210> 472
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SELECTIN
      ANTAGONIST PEPTIDE
<400> 472
Xaa Lys Xaa Lys Thr Xaa Glu Ala Xaa Asn Trp Xaa Xaa
                                     10
  1
<210> 473
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SOMATOSTATIN/
      CORTISTATIN-MIMETIC PEPTIDE
<220>
<223> At position 1, Xaa is asp-arg-met-pro-cys,
      arg-met-pro-cys, met-pro-cys, pro-cys, or cys
<220>
```

<223> At position 2, Xaa is arg or lys

<220>

<223> At position 10, Xaa is ser or thr

<220>

<223> At position 12, xaa is cys:lys or cys

<400> 473

Xaa Xaa Asn Phe Phe Trp Lys Thr Phe Xaa Ser Xaa 1 10

<210> 474

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN-MIMETIC PEPTIDE

<400> 474

Asp Arg Met Pro Cys Arg Asn Phe Phe Phe Trp Lys Thr Phe Ser Ser 1 15

Cys Lys

<210> 475

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN-MIMETIC PEPTIDE

<400> 475

Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 .10 15

<210> 476

<211> 13 ...

<212> PRT

<213> Artificial Sequence

<220> <223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN-MIMETIC PEPTIDE <400> 476 Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys 10 5 1 <210> 477 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN-MIMETIC PEPTIDE <400> 477 Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 10 15 1 <210> 478 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE <400> 478 Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys 10 1

<210> 479
<211> 12
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: SOMATOSTATIN/

## CORTISTATIN MIMETIC PEPTIDE

<210> 480

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 480

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 10 15

<210> 481

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 481

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys
1 5 10 15

<210> 482

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 482

```
Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys Lys

1 . 5 10
```

<210> 483

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 483

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys

1 10 15

<210> 484

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Fc-TMP

<400> 484

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys
1 10

<210> 485

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 485

Cys Lys Asn Phe Phe Trp Lys Thr Phe Ser Ser Cys

1 5 10

```
<210> 486
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SOMATOSTATIN/
      CORTISTATIN MIMETIC PEPTIDE
<400> 486
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
                                     10
                                                         15
  1
Lys
<210> 487
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SOMATOSTATIN/
      CORTISTATIN MIMETIC PEPTIDE
<400> 487
Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
<210> 488
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SOMATOSTATIN/
      CORTISTATIN MIMETIC PEPTIDE
<400> 488
Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
                                     10
```

WO 00/24782 PCT/US99/25044

```
<210> 489
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SOMATOSTATIN/
      CORTISTATIN MIMETIC PEPTIDE
<400> 489
Asp Arg Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
                                                          15
                                     10
<210> 490
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SOMATOSTATIN/
      CORTISTATIN MIMETIC PEPTIDE
<400> 490
Met Pro Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
                                      10
  1
<210> 491
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: SOMATOSTATIN/
      CORTISTATIN MIMETIC PEPTIDE
```

<210> 492 <211> 17

<400> 491

10

Cys Arg Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys

```
<212> PRT
```

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 492

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 10 15

Lys

<210> 493

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 493

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
1 5 10 15

<210> 494

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 494

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys Lys
1 5 10

<210> 495

<211> 16

```
<212> PRT
```

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 495

Asp Arg Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys

1 10 15

<210> 496

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 496

Met Pro Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 497

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SOMATOSTATIN/ CORTISTATIN MIMETIC PEPTIDE

<400> 497

Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys

1 10

<210> 498

<211> 25

<212> PRT

<213> Artificial Sequence

WO 00/24782 PCT/US99/25044

<220>

<223> Description of Artificial Sequence: CAP37
MIMETIC/LPS BINDING PEPTIDE

<400> 498

Asn Gln Gly Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe 1 5 10 15

Val Met Thr Ala Ala Ser Cys Phe Gln
20 25

<210> 499

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CAP37
MIMETIC/LPS BINDING PEPTIDE

<400> 499

Arg His Phe Cys Gly Gly Ala Leu Ile His Ala Arg Phe Val Met Thr
1 10 15

Ala Ala Ser Cys

20

<210> 500

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CAP37 MIMETIC/LPS BINDING PEPTIDE

<400> 500

Gly Thr Arg Cys Gln Val Ala Gly Trp Gly Ser Gln Arg Ser Gly Gly
1 10 15

Arg Leu Ser Arg Phe Pro Arg Phe Val Asn Val

```
WO 00/24782
```

<210> 501

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF-ANTAGONIST PEPTIDE

<400> 501

Gly Glu Arg Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Trp

1 10 15

Glu Ile

<210> 502

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: VEGF ANTAGONIST PEPTIDE

<400> 502

Glu Glu Leu Trp Cys Phe Asp Gly Pro Arg Ala Trp Val Cys Gly Tyr
1 5 10 15

Val Lys

<210> 503

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ANTIPATHOGENIC PEPTIDE

<400> 503

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys

WO 00/24782 PCT/US99/25044

1 5 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln
20 .25 30

Gln

<210> 504

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ANTIPATHOGENIC PEPTIDE

<220>

<223> At positions 7, 18 and 19, D amino acid residue

<400> 504

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
1 10 15

Thr Leu Leu Ser Ala Val Gly Ser Ala Leu Ser Ser Ser Gly Gly Gln 20 25 30

Glu

<210> 505

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: ANTIPATHOGENIC PEPTIDE

<220>

<223> At positions 18 and 19, D amino acid residues

<400> 505

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys

PCT/US99/25044

1 5 10 15

Thr Leu Leu Ser Ala Val 20

<210> 506

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC PEPTIDE

<220>

<223> At positions 7, 18 and 19, D amino acid residues

<400> 506

Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe Lys
1 10 15

Thr Leu Leu Ser Ala Val

20

<210> 507

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VIP MIMETIC PEPTIDE

<220>

<223> At positions 8, 19 and 20, D amino acid residues

<400> 507

Lys Gly Phe Phe Ala Leu Ile Pro Lys Ile Ile Ser Ser Pro Leu Phe 1 5 10 15

Lys Thr Leu Leu Ser Ala Val

20